株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

禁煙市場:データ・分析・予測

Smoking Cessation - Data, Analysis & Forecasts to 2023

発行 GMR Data Ltd 商品コード 301553
出版日 ページ情報 英文 101 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。
Back to Top
禁煙市場:データ・分析・予測 Smoking Cessation - Data, Analysis & Forecasts to 2023
出版日: 2013年10月04日 ページ情報: 英文 101 Pages
概要

世界の禁煙市場は、2023年には44億ドルの規模に成長すると予測されています。ニコチン代替療法(NRT)ではNicodermおよびHabitrolが主要製品となっており、世界市場における収益の80%以上を占めています。一方、処方薬ではブプロピオンおよびバレニクリンが主要製品となっています。

当レポートでは、世界の禁煙製品市場の見通しについて調査分析し、タバコ消費の動向、禁煙・禁煙製品利用への各種影響因子、主な治療製品/治療薬、主要国における動向と市場成長予測、主要企業のプロファイル、SWOT分析などをまとめ、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 禁煙:イントロダクション

  • 禁煙治療の概要
    • ニコチン代替療法(NRT)
    • 非NRT治療
  • 世界のタバコ消費の動向・影響
    • タバコに起因する死亡
    • 受動喫煙
    • 喫煙に関連した健康被害への意識の拡大
    • タバコ製品の広告・販促の禁止強化
    • 増税

第3章 禁煙市場の予測

  • 世界の禁煙市場
    • 世界の禁煙市場
    • 世界の処方禁煙薬市場

第4章 主要国市場の予測

  • 米国:世界市場の45-50%を占める見通し
  • 英国:成熟市場の成長の余地
  • フランス:世界市場におけるフランスのシェア
  • ドイツ:タバコ消費量の減少と禁煙市場
  • スペイン:EUでもっとも厳しい禁煙法とその影響
  • イタリア:電子タバコの好調な売上と他のNRT製品への影響
  • 日本:低い成長率を示す理由
  • その他の地域:インド、中国などの新興市場の世界市場への影響

第5章 ニコチン代替療法(NRT)市場

  • NicoDerm CQ
  • Nicotrol
  • Habitrol(Nicotinell)
  • Nicorette

第6章 処方薬市場

  • Chantix(Pfizer):バレニクリン
  • Zyban/Wellbutrin(GS):ブプロピオン

第7章 主要企業

  • Pfizer
  • GlaxoSmithKline (GSK)
  • Novartis
  • Johnson & Johnson (J&J)
  • Perrigo
  • Sophomore and Extab
  • 22nd Century Group, Inc.

第8章 SWOT分析

第9章 専門家へのインタビュー

  • Pfizer
  • Elder Pharmaceuticals
  • GlaxoSmithKline

図表

目次
Product Code: CB1

In April 2013 the US Food & Drug Agency (FDA) announced its plan to relax rules regarding the use and labelling of over-the-counter nicotine replacement therapies.

On April 1st 2013, FDA Commissioner Margaret A. Hamburg M.D. stated, "The agency heard from several public health groups that the labelling for OTC NRT products may stop consumers who are trying to quit smoking from using them. The FDA hopes the recommended changes will allow more people to use these products effectively for smoking cessation and that tobacco dependence will decline in this country." Will new changes increase take-up of smoking cessation products? This report tells you.

The global smoking cessation market is forecast to reach $4.4bn in 2023, but what will it be this year? Next year? and in 5 years time?

GMR Data's new smoking cessation report outlines the key factors affecting the market across the forecast period 2013-2023. The report outlines essential drivers and restraints in all key global geographies.

Nicoderm and Habitrol are the primary NRT products on the market, accounting for over 80% of the global NRT market revenue in 2013. Bupropion and Varenicline are the major products in the prescription drug segment of the smoking cessation market. But what are the 5 key drivers of the global smoking cessation market?

  • 1) Increased health care / health education in many geographies
  • 2) Adoption of smoking cessation products onto health insurance policies
  • 3) Increasing number of smoking cessation products emerging onto the market
  • 4) Emergence of e-cigarettes onto the global market
  • 5) Over 1bn smokers worldwide

This report analysis your market, in key geographic segments; explains in which direction each key market will grow across the next 10 years, and why. Can you afford to ignore this report?

Key challenges for you & your competition

The key challenges that must be faced in the smoking cessation market include; a weak R&D pipeline, off putting side effects affecting key smoking cessation drugs and the challenge of multiple e-cigarette brands encroaching the traditional NRT marketplace. Only by ordering this in-depth exclusive report will you have full access to the unique findings. This information is not available anywhere else. Find full details of these approved drugs alongside key cancer drugs in their testing phases in this new GMR Data report.

This report also breaks down the market in terms of current smoking cessation drugs and products that occupy the market at present; examining the key prescription and OTC drugs that drive the market. In addition to this crucial information this report offers analysis and opinion on current R&D in the smoking cessation sector alongside in depth analysis of the emerging, global e-cigarette market.

Discover exactly what the industry leaders are doing TODAY -

Within GMR Data's 'Smoking Cessation - Data, Analysis & Forecasts to 2023' we analyse the key cessation products and drugs in the market currently and how they will perform across the next decade. Our study focuses on the individual revenues of the top Smoking Cessation products. With variable patents and the threat of generics, how will these key products fare across the next decade? - ONLY THIS UNIQUE REPORT WILL TELL YOU We also include analysis of key NRT (Nicotine Replacement Therapies such as NicoDerm CQ; Nicotrol; Habitrol (Nicotinell) and Nicorette. Also analysed are the prescription drugs for smoking cessation, such as: Chantix (by Pfizer): Varenicline and Zyban / Wellbutrin (by GSK): bupropion. With assessment of the leading players in smoking cessation including: Pfizer; GlaxoSmithKline (GSK); Novartis; Johnson & Johnson (J&J); Perrigo; Sophomore and Extab plus 22nd Century Group, Inc.

PLUS - In-depth country analysis - Discover which countries and regions will drive the smoking cessation drugs market to 2023? Prescription drugs in the smoking cessation have proved popular and, to some extent, effective. However, side effects and increasingly severe FDA warnings have put some potential customers off. What this means is that there is still space in the market for new pipeline drugs, with fewer side effects and greater efficacy. But how will these prescription markets develop? This report will tell you - TODAY

Industry information sourced exclusively for this report. This information is not available anywhere else

Utilising primary and secondary research sources, GMR Data have interviewed leading smoking cessation specialists within big pharma, R&D, wholesalers, distributors, marketeers and key organisations. From these interviews we have selected original, exclusive, transcribed interviews with leading specialists in their field - This information is not available anywhere else.

This GMR Data report is the single tool to equip you with the latest trends in all regional markets and why all stakeholders demand development of Smoking Cessation products. This report will arm you with all you and your company require to develop, price, launch and market a smoking cessation product.

With over 100+ pages, and over 85+ pages of charts, tables, figures and graphs, this dedicated specialist report will ensure you remain equipped and fully informed, to succeed in this competitive market.

Table of Contents

1 Executive Summary

  • 1.1. Smoking Cessation Market Review
  • 1.2. Chapter Breakdown
  • 1.3. Research and Analysis Methods

2 Introduction to Smoking Cessation

  • 2.1. Smoking Cessation Treatment Overview
    • 2.1.1. Nicotine Replacement Therapy (NRT)
    • 2.1.2. Non-NRT Therapy
  • 2.2. Global Tobacco Consumption Prevalence, Trends & Impact
    • 2.2.1. Prevalence of Death Caused due to Tobacco
    • 2.2.2. Second-Hand Smoking
    • 2.2.3. Increased Awareness of Health Implications in Relation to Smoking
    • 2.2.4. Enforcement of Bans on Tobacco Product Advertising & Promotions
    • 2.2.5. Increased Taxation

3 Smoking Cessation Market Forecasts

  • 3.1. Global Smoking Cessation Market
    • 3.1.1. Global Smoking Cessation Market
    • 3.1.2. Global Prescription Drugs Smoking Cessation Market

4 Key Global Smoking Cessation Markets 2013-2023

  • 4.1. The US Smoking Cessation Market - Set to Occupy 45-50% of the Global Market Across 2013- 2023
  • 4.2. The UK Smoking Cessation Market - How Will This Mature Market Grow Through 2013-2023?
  • 4.3. The France Smoking Cessation Market - How Much of the Global Smoking Cessation Market Will France Occupy to 2023?
  • 4.4. The German Smoking Cessation Market - Will Reduced German Tobacco Consumption Drive The Smoking Cessation Market?
  • 4.5. The Spanish Smoking Cessation Market - The Strictest Anti-Smoking Laws in the EU, How Will This Affect The Spanish Smoking Cessation Market?
  • 4.6. The Italian Smoking Cessation Market - How Will Strong E-cigarette Sales Affect Other NRT Products in the Italian Smoking Cessation Market?
  • 4.7. The Japanese Smoking Cessation Market - Why Does GMR Data Forecast a Low Growth Rate in the Japanese Smoking Cessation Market?
  • 4.8. The Rest of World Smoking Cessation Market - How Will Emerging Markets, Such as India & China, Affect theGlobal Smoking Cessation Market Across 2013-2023?

5 Nicotine Replacement Therapies (NRT) Market

  • 5.1. NicoDerm CQ
  • 5.2. Nicotrol
  • 5.3.Habitrol (Nicotinell)
  • 5.4.Nicorette

6 Prescription Drugs Smoking Cessation Market

  • 6.1.Chantix (by Pfizer): Varenicline
  • 6.2.Zyban / Wellbutrin (by GSK): bupropion

7 Leading Companies in the Global Smoking Cessation Market

  • 7.1. Pfizer
  • 7.2. GlaxoSmithKline (GSK)
  • 7.3. Novartis
  • 7.4. Johnson & Johnson (J&J)
  • 7.5. Perrigo
  • 7.6. Sophomore and Extab
  • 7.7. 22nd Century Group, Inc.

8 SWOT Analysis of the Smoking Cessation Market

  • 8.1. Strengths
    • 8.1.1. FDA Relaxation in the NRT Market
    • 8.1.2. Increased Insurance Cover for Smoking Cessation Products
    • 8.1.3. Strong Mature Markets
  • 8.2. Weaknesses
    • 8.2.1. Weak R&D pipeline for the smoking cessation market
    • 8.2.2. Side Effects to Current Drugs/Therapies on the Market
  • 8.3. Opportunities
    • 8.3.1. E-cigarettes
      • 8.3.1.1. E-cigarettes Legal Status
      • 8.3.1.2. E-cigarettes Background
      • 8.3.1.3. Geographic Breakdown & Market Share for E-cigarettes
      • 8.3.1.4. Market Forecast
      • 8.3.1.5. E-cigarette Industry Regulation
    • 8.3.2. Future Research on Drugs/Therapies Currently on the Market
    • 8.3.3. Strong Emerging Markets
  • 8.4. Threats
    • 8.4.1. Pool of Smokers Greatly Reduced in Some Key Markets
    • 8.4.2. New Drug / Product threat

9 Expert Interviews

  • 9.1. Pfizer
  • 9.2. Elder Pharmaceuticals
  • 9.3. GlaxoSmithKline

List of Tables

  • Table 2.2.1 Prevalence of tobacco use among adults in selected countries-males and females, 2010
  • Table 2.2.2: Non-Smoking Adults Working Indoors Who Are Exposed to Second-hand Tobacco Smoke, 2008 - 2010
  • Table 2.2.3: BRIC Population, GDP per Capita 2000 & 2010 ($/per annum)
  • Table 2.2.3.1: Smokers Reporting Six Months Continued Cessation with Different Interventions
  • Table 2.2.3.2: Adult Smokers Who Do Not Believe, or Do Not Know That Smoking Causes Specific Diseases, by Country
  • Table 3.1 Global Smoking Cessation Market Forecast 2013-2023 ($m)
  • Table 3.1.a: Key NRT Products Revenue Forecast 2013, 2018 & 2023 ($/m)
  • Table 3.1.b Global Smoking Cessation Market - Breakdown ($m)
  • Table 3.1.1 Global NRT Smoking Cessation Market Forecast 2013-2023 ($/m)
  • Table 3.1.2 Global Prescription Drugs Smoking Cessation Market Forecast 2013-2023 ($/m)
  • Table 4.a The Global Smoking Cessation Market Forecast 2012 -2023, by Country ($/m per annum)
  • Table 4.b Key Countries CAGR 2013-2023 (%)
  • Table 4.c Estimated Smoking Cessation Market Share for Selected Countries 2013, 2018 and 2023 (%)
  • Table 4.1 the US Smoking Cessation Market Forecast 2011-2023 ($/m)
  • Table 4.2 the UK Smoking Cessation Market Forecast 2012-2023 ($/m)
  • Table 4.2.1 EU5 Total Population & Population of Smokers 2012
  • Table 4.3 the France Smoking Cessation Market Forecast 2011-2023 ($ Million)
  • Table 4.4 the German Smoking Cessation Market Forecast 2011-2023 ($/m)
  • Table 4.4.1 Amount of Tobacco Sold in Germany 1995-2010 (Tonnes)
  • Table 4.5 the Spanish Smoking Cessation Market Forecast 2011-2023 ($ Million)
  • Table 4.5.1 The number of smokers in Spain (Million)
  • Table 4.6 The Italian Smoking Cessation Market Forecast 2011-2023 ($/m)
  • Table 4.7 the Japanese Smoking Cessation Market Forecast 2011-2023 ($/m)
  • Table 4.8 The Rest of the World Smoking Cessation Market Forecast 2011-2023 ($ Million)
  • Table 4.8.1 Estimated Smoking Cessation Market Share for Selected Countries 2013, 2018 and 2023 (%)
  • Table 4.8.2 BRIC Population, GDP 2000 & 2010, CAGR & GDP per Capita 2000 & 2010 ($/per annum)
  • Table 5.1 Market Forecast for Nicoderm CQ 2013-2023
  • Table 5.2 Global Nicotrol Market 2010-2012 ($m)
  • Table 5.2.1 Global Nicotrol Market Forecast 2013-2023 ($/m)
  • Table 5.3 Market Forecast for Habitrol/Nicotinell 2013-2023
  • Table 5.4 Market Forecast for Nicorette 2013-2023
  • Table 6 Tobacco Cessation Medications and Associated Side Effects
  • Table 6.1 Global Chantix/ Champix Market 2008 - 2012
  • Table 6.1.a Market Forecast for Chantix / Champix 2013-2023
  • Table 6.2 Market Forecast for Zyban 2013-2023
  • Table 7.1 Pfizer Smoking Cessation Pipeline
  • Table 7.2 Global Chantix / Champix Market 2008-2012
  • Table 7.3 Market Forecast for Chantix / Champix 2013-2023
  • Table 7.4 Market Forecast for Zyban 2013-2023
  • Table 8 SWOT Analysis
  • Table 8.1.3 US, UK, France & Japanese Smoking Cessation Markets 2012-2016 ($/ per annum)
  • Table 8.2.1 NRT Products Pipeline
  • Table 8.2.1.a Smoking Cessation Drugs /Products Pipeline
  • Table 8.2.2 Side Effects of major smoking cessation products
  • Table 8.3.1.2 Major E-cigarette Brands
  • Table 8.3.1.4 Market Forecast for E-Cigarettes 2013-2023
  • Table 8.3.1.4.a Costs per pack of cigarettes in Key countries
  • Table 8.3.3ROW Smoking Cessation Market Share 2013
  • Table 8.3.3.a Chinese & Indian Populations, Number of Smokers, GDP in 2000 & 2010 ($)

List of Figures

  • Figure 2.2.1: Prevalence of tobacco use among adults in selected countries-males and females, 2010
  • Figure 2.2.4.1 Global Market Size as per Skin Cancer Type - Incidences
  • Figure 2.2.2 Non-Smoking Adults Working Indoors Who Are Exposed to Second-hand Tobacco Smoke, 2008 - 2010
  • Figure 2.2.3 Adult Smokers Who Do Not Believe, or Do Not Know That Smoking Causes Specific Diseases, by Country
  • Chart 2.2.5: Average Retail Price and Taxation (Excise and Total) of Most Sold Brands of Cigarettes, 2010
  • Figure 3.1 Global Smoking Cessation Market Forecasts 2013 to 2023
  • Figure 3.1.1 Global NRT Smoking Cessation Market Forecast 2013-2023
  • Figure 3.1.1.a Global NRT Smoking Cessation Market Share by Product Type
  • Figure 3.1.2 Global Prescription Drugs Smoking Cessation Market Forecast 2013-2023 GMR Data 2013
  • Figure 4.a Global Market Share for Selected Countries 2013
  • Figure 4.b Global Market Share for Selected Countries 2018
  • Figure 4.c Global Market Share for Selected Countries 2023
  • Figure4.1. The US Smoking Cessation Market Forecast 2012-2023 ($/m)
  • Figure 4.2 Retail Sales of NRT Products in the UK 2012
  • Figure 4.2.a. The UK Smoking Cessation Market Forecast 2012-2023 ($ Million)
  • Figure 4.3. The France Smoking Cessation Market Forecast 2012-2023 ($ Million)
  • Figure 4.4 The German Smoking Cessation Market Forecast 2012-2023 ($ Million)
  • Figure 4.5. The Spanish Smoking Cessation Market Forecast 2012-2023 ($ Million)
  • Figure 4.6 The Italian Smoking Cessation Market Forecast 2012-2023 ($/m)
  • Figure 4.7 The Japanese Smoking Cessation Market Forecast 2012-2023 ($ Million)
  • Figure 4.8 The ROW Smoking Cessation Market Forecast 2012-2023 ($ Million)
  • Figure 5.1 Market Forecast for Nicoderm CQ 2013-2023
  • Figure 5.1.a Geographic Breakdown for Nicoderm CQ 2012 & 2023
  • Figure 5.2 Global Revenue for Nicotrol 2010-2012
  • Figure 5.2.1 Global Market Forecast for Nicotrol 2013-2023
  • Figure 5.3 Market Forecast for Habitrol/Nicotinell 2013-2023
  • Figure 5.4 Market Forecast for Nicorette 2013-2023
  • Figure 6.1 Global Chantix/ Champix Market 2008 - 2012
  • Figure 6.1.a Global Chantix/ Champix Market 2013 - 2023
  • Figure 6.1.b Geographic Breakdown for Chantix / Champix 2012 & 2023
  • Figure 6.2 Global Zyban Market 2013 - 2023
  • Figure 8.3.1.3 Geographic Breakdown
  • Figure 8.3.1.3.1 Market Share of e-cigarette Sales in the US Convenience Stores by Brand
  • Figure 8.3.1.4 Market Forecast for E-Cigarettes 2013-2023
Back to Top